Highlights Silo Pharma, Inc.

Equities

SILO

US82711P2011

Delayed Nasdaq Other stock markets 09:26:59 17/05/2024 pm IST			5-day change	1st Jan Change
2.01 ^USD	+6.91%		+19.64%	+39.58%

23/04	Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment	CI
10/04	Silo Pharma Says It Exercised Option to License Alzheimer's Therapeutic From Columbia University	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment	23/04	CI
Silo Pharma Says It Exercised Option to License Alzheimer's Therapeutic From Columbia University	10/04	MT
Tranche Update on Silo Pharma, Inc.'s Equity Buyback Plan announced on January 31, 2023.	06/04	CI
Silo Pharma, Inc.'s Equity Buyback Plan Extended till March 31, 2024.	04/04	CI
Tranche Update on Silo Pharma, Inc.'s Equity Buyback Plan announced on January 31, 2023.	26/03	CI
Silo Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03	CI
Silo Pharma, Inc. Exercises Option for Exclusive License Agreement for First-In-Class PTSD and Stress-Induced Anxiety Therapeutic	20/03	CI
Silo Pharma, Inc. Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain	18/03	CI
Silo Pharma?s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery	14/02	CI
Silo Pharma, Inc. Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology	01/02	CI
Silo Pharma Announces Positive Results in Alzheimer?s Disease Study	24/01	CI
Silo Pharma, Inc.'s Equity Buyback Plan Extended till March 31, 2024.	09/01	CI
Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD	04/01	CI
Silo Pharma, Partner Receive Regulatory Approval to Develop Ketamine Implant for Fibromyalgia Treatment	28/12	MT
Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia	28/12	CI
Tranche Update on Silo Pharma, Inc.'s Equity Buyback Plan announced on January 31, 2023.	14/11	CI
Silo Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Silo Pharma, Inc. to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD	08/11	CI
Silo Pharma?s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis	16/23/16	CI
Silo Pharma, Inc. Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug Application with FDA	20/23/20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Silo Pharma, Inc.

Equities

SILO

US82711P2011

Highlights

Filters